Overview

* MiMedx ( MDXG ) Q3 net sales rise 35% yr/yr, beating analyst expectations

* Adjusted EBITDA for Q3 beats estimates, driven by product sales growth

* Company raises 2025 net sales growth and adjusted EBITDA expectations

Outlook

* MiMedx ( MDXG ) expects 2025 net sales growth in the mid-to-high teens percentage vs 2024

* Company anticipates 2025 adjusted EBITDA margin at least mid-20% range on full year basis

* MiMedx ( MDXG ) sees long-term annual net sales growth in low double-digits percentage

Result Drivers

* WOUND PRODUCT SALES - 40% increase in Wound product sales driven by CELERA and EMERGE

* SURGICAL PRODUCT SALES - 26% increase in Surgical product sales, including growth in AMNIOFIX, AMNIOEFFECT, and HELIOGEN

* GROSS MARGIN IMPROVEMENT - Year-over-year increase in gross margin driven by product mix

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $113.72 $94.14

mln mln (4

Analysts

)

Q3 Net $16.74

Income mln

Q3 Beat $34.95 $19.35

Adjusted mln mln (2

EBITDA Analysts

)

Q3 Gross $95 mln

Profit

Q3 $22.19

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for MiMedx Group Inc ( MDXG ) is $12.00, about 42.7% above its October 28 closing price of $6.88

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)